Assignee
VALO HEALTH INC
US·29 granted patents·12 pending applications·36 citations·filing 2017–2025
Top patents by PatentIndex Score
41 records- 0198US11279681B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 22, 2022·6 cites·20 claims
- 0297US11702412B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Jul 18, 2023·4 cites·18 claims
- 0396US12213969B22-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitorsVALO HEALTH INC·Filed 2023·Granted Feb 4, 2025·2 cites·20 claims
- 0496US11730721B22-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Aug 22, 2023·3 cites·20 claims
- 0595US11548886B2Monocyclic compounds useful as GPR120 modulatorsVALO HEALTH INC·Filed 2020·Granted Jan 10, 2023·4 cites·10 claims
- 0692US11891365B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2021·Granted Feb 6, 2024·1 cites·23 claims
- 0791US11547701B2Compounds and compositions for the inhibition of NAMPTVALO HEALTH INC·Filed 2020·Granted Jan 10, 2023·2 cites·11 claims
- 0891US11485745B2Amido spirocyclic amide and sulfonamide derivativesVALO HEALTH INC·Filed 2020·Granted Nov 1, 2022·2 cites·19 claims
- 0991US11279687B2Compounds and compositions for the inhibition of NAMPTVALO HEALTH INC·Filed 2020·Granted Mar 22, 2022·2 cites·9 claims
- 1089US11274084B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 15, 2022·1 cites·18 claims
- 1187US11345672B2Methods using HDAC11 inhibitorsVALO HEALTH INC·Filed 2019·Granted May 31, 2022·2 cites·19 claims
- 1285US12264137B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2022·Granted Apr 1, 2025·0 cites·17 claims
- 1385US11479564B2Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)VALO HEALTH INC·Filed 2020·Granted Oct 25, 2022·1 cites·7 claims
- 1484US12304904B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2023·Granted May 20, 2025·0 cites·20 claims
- 1584US10865201B2Bicyclic compounds useful as GPR120 modulatorsVALO HEALTH INC·Filed 2017·Granted Dec 15, 2020·4 cites·20 claims
- 1683US12336981B2Compounds and compositions for the inhibition of NAMPTVALO HEALTH INC·Filed 2022·Granted Jun 24, 2025·0 cites·11 claims
- 1782US11535607B2Isoindolines as HDAC inhibitorsVALO HEALTH INC·Filed 2019·Granted Dec 27, 2022·2 cites·16 claims
- 1882US2023406830A1[6,6] fused bicyclic hdac8 inhibitorsVALO HEALTH INC·Filed 2023·Application pending·0 cites
- 1980US12479807B2Methods using HDAC11 inhibitorsVALO HEALTH INC·Filed 2022·Granted Nov 25, 2025·0 cites·2 claims
- 2080US11919839B2Alpha-cinnamide compounds and compositions as HDAC8 inhibitorsVALO HEALTH INC·Filed 2021·Granted Mar 5, 2024·0 cites·20 claims
- 2179US11274085B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 15, 2022·0 cites·15 claims
- 2278US12116362B2Monocyclic compounds useful as GPR120 modulatorsVALO HEALTH INC·Filed 2022·Granted Oct 15, 2024·0 cites·21 claims
- 2378US2024287031A1Process for preparing 6-substituted-1-(2h)-isoquinolinones and intermediate compoundVALO HEALTH INC·Filed 2024·Application pending·0 cites
- 2478US2023110003A1Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)VALO HEALTH INC·Filed 2022·Application pending·0 cites
- 2578US2024287030A1Process for preparing 6-substituted-1-(2h)-isoquinolinones and intermediate compoundVALO HEALTH INC·Filed 2024·Application pending·0 cites
- 2675US2025296923A1Process for preparing 6-substituted-1-(2h)-isoquinolinones and intermediate compoundVALO HEALTH INC·Filed 2025·Application pending·0 cites
- 2773US11795171B2Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitorsVALO HEALTH INC·Filed 2021·Granted Oct 24, 2023·0 cites·10 claims
- 2873US11414392B2[6,6] fused bicyclic HDAC8 inhibitorsVALO HEALTH INC·Filed 2020·Granted Aug 16, 2022·0 cites·20 claims
- 2972US12018030B2Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitorsVALO HEALTH INC·Filed 2021·Granted Jun 25, 2024·0 cites·16 claims
- 3067US11919891B2Bicyclic compounds useful as GPR120 modulatorsVALO HEALTH INC·Filed 2020·Granted Mar 5, 2024·0 cites·20 claims
- 3166US2025346599A1Tricyclic phthalazinone parp inhibitors and methods of useVALO HEALTH INC·Filed 2023·Application pending·0 cites
- 3263US2023242512A1Isoindolines as hdac inhibitorsVALO HEALTH INC·Filed 2022·Application pending·0 cites
- 3362US11325917B2Thienopyrazine carboxamides as ubiquitin-specific protease inhibitorsVALO HEALTH INC·Filed 2020·Granted May 10, 2022·0 cites·20 claims
- 3461US2025263405A1Histone deacetylase 6 inhibitor compounds and uses thereofVALO HEALTH INC·Filed 2022·Application pending·0 cites
- 3557US12252490B2Inhibiting deubiquitinase USP25 and USP28VALO HEALTH INC·Filed 2019·Granted Mar 18, 2025·0 cites·15 claims
- 3657US2024060052A1Artificial Skeletal Muscle TissueVALO HEALTH INC·Filed 2023·Application pending·0 cites
- 3753US12590087B2Inhibiting USP36VALO HEALTH INC·Filed 2020·Granted Mar 31, 2026·0 cites·11 claims
- 3851US2022213059A1Inhibiting usp19VALO HEALTH INC·Filed 2020·Application pending·0 cites
- 3949US2022204495A1Inhibiting trabidVALO HEALTH INC·Filed 2020·Application pending·0 cites
- 4047US12595449B2Integrated system for 3D tissue cultureVALO HEALTH INC·Filed 2021·Granted Apr 7, 2026·0 cites·13 claims
- 4144US2023143572A1Artificial skeletal muscle tissueVALO HEALTH INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when VALO HEALTH INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →